

References

- Amdisen, A. 1975. Sustained-release preparations of lithium. In Johnson (ed.), Lithium Research and Therapy , pp. 197 - 210. New York : Academic Press.
- Amdisen, A. 1977. Serum level monitoring and clinical pharmacokinetics of lithium. Clinical Pharmacokinetic 2 : 73 - 92.
- Amdisen, A. 1983. Serum Level Monitoring and Clinical Pharmacokinetics of Lithium. In M.Gibaldi, and L.Prescott (eds.) , Handbook of Clinical Pharmacokinetics , pp. 109 - 131. NEW : ADIS Health Science.
- Amdisen, A., and Carson, S.W. 1986. Lithium. In W.E. Evans ,J.J. Schentag, and W.J. Jusko (eds.) , Applied Pharmacokinetics : Principles of Therapeutic Drug Monitoring , pp. 978 - 1008. Spokane WA : Applied Therapeutic, Inc.
- Carson, S.W. 1992. Lithium. In W.E. Evans, J.J. Schentag, and W.J. Jusko (eds.) , Applied Pharmacokinetics : Principles of Therapeutic Drug Monitoring, pp. 34-2 - 34-26. Vancouver : Applied Therapeutics, Inc.
- Cooper, T.B., Bergner, P.E.E., and Simpson, G.M. 1973. The 24-hour serum level as a prognosticator of dosage requirements. American Journal of Psychiatry 130 : 601 - 603.

- Cooper, T.B., and Simpson, G.M. 1976. The 24-hour lithium level as a prognosticator of dosage requirements : A two-year follow-up study. American Journal of Psychiatry 133 : 440 - 443.
- Ereshefsky, L., and Jann, M.W. 1983. Lithium. In D. Mungall (ed.) , Applied Clinical Pharmacokinetics , pp. 245 - 270. New York : Raven Press.
- Ereshefsky, L., Gilderman, A.M. , and Jewett, C.H. 1979a. Lithium Therapy of Manic Depressive Illness Part I : Target Symptoms, Pharmacology & Kinetics. Drug Intelligence and Clinical Pharmacy 13 : 403 - 408.
- Ereshefsky, L., Gilderman, A.M., and Jewett, C.H. 1979b. Lithium Therapy of Manic Depressive Illness Part II : Monitoring. Drug Intelligence and Clinical Pharmacy 13 : 492 - 497.
- Fast, G.A., and Preskorn, S.H. 1993. Therapeutic Drug Monitoring. In D. Dunner (ed.) , Current Psychiatric Therapy , pp. 529 - 534. Philadelphia : W. B. Saunders.
- Goodwin, F.K., and Jamison, K.R., eds. 1990. Manic-Depressive Illness. New York : Oxford University Press.
- Jefferson, J.W. 1990. Lithium : the present and the future. Journal of Clinical Psychiatry 51 (suppl 8) : 4 - 19.
- Karki, S.D., and Holden, J.M.C. 1988. Appropriateness of The Use of Serum Lithium Assays. Drug Intelligence and Clinical Pharmacy 22 : 151 - 153.

- Laraia, M.T., and Stuart, G.W. 1995. Quick Psychopharmacology Reference St.Louis : Mosby Year Book,Inc.
- Lenox, R.H., and Manji, H.K. 1995. Lithium. In A.F. Schatzberg, and C.B. Nemeroff (eds.) , The American Psychiatric Press Textbook of Psychopharmacology , pp. 303 - 349. NW Washington : American Psychiatric Press.
- Peet, M., and Pratt, J.P. 1993. Lithium : Current Status in Psychiatric Disorders. Drugs 46 : 7 - 17.
- Salem, R.B., Muniz, C.E., and Director, K. 1980. Ataxia as the primary symptom of lithium toxicity. Drug Intelligence and Clinical Pharmacy 14 : 622- 623.
- Salem, R.B. 1982. A Pharmacist's Guide to Monitoring Lithium Drug - Drug Interaction. Drug Intelligence and Clinical Pharmacy 16 : 745 - 747.
- Salem, R.B. 1983. Recommendation for Monitoring Lithium Therapy. Drug Intelligence and Clinical Pharmacy 17 : 346 - 350.
- Sarid-segal, O., Creelman, W.L., Ciraulo, D.A., and Shader, R.I. 1995. Lithium. In D.A. Ciraulo, R.I. Shader, D.J. Greenblatt, and W.L. Creelman (eds.) , Drug Interactions In Psychiatry , pp. 175 - 213. Baltimore Maryland : Williams & Wilkins.
- Stimmel, G.L., and Wincor, M.Z. 1986. Mental Health Pharmacy. In T.R. Brown, and M.C. Smith (eds.) , Handbook of Institutional Pharmacy Practice, pp. 535 - 544. Baltimore Maryland : Williams & Wilkins.

- USP. 1994. USP DI : Drug Information for the Health Care Professional.
Rockville,MD : U.S. Pharmacopeial Convention.
- Vertrees, J., and Ereshefsky, L. 1995. Lithium. In G.E. Schumacher (ed.)
, Therapeutic Drug Monitoring , pp. 493 - 526. Norwalk Connecticut
:Appleton & Lange.
- Ward, M.E., Musa, M.N., and Bailey, L. 1994. Clinical Pharmacokinetics of
Lithium. Journal of Clinical Pharmacology 34 : 280 - 285.
- Winter, M.E., Koda-Kimble, M.A., and Young, I.Y., eds. 1992. Basic
Clinical Pharmacokinetics . Vancouver : Applied Therapeutics, Inc.
- Yukawa, E., Nomiya, N., Higuchi, S., and Aoyama, T. 1993. Lithium
Population Pharmacokinetics from Routine Clinical Data : Role of
Patient Characteristics for Estimating Dosing Regimens. Therapeutic
Drug Monitoring 15 : 75 - 82.

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX A

Equations:

$$\text{Equation 1 : CrCl (male) = } \frac{(140 - \text{Age})(\text{Weight})}{(72)(\text{Scr})} \quad \text{mL/min}$$

$$\text{Equation 2 : CrCl (female) = } \frac{(0.85)(140 - \text{Age})(\text{Weight})}{(72)(\text{Scr})} \quad \text{mL/min}$$

$$\text{Equation 3 : Lithium clearance = } (0.25)(\text{CrCl})(0.06) \quad \text{L/hr}$$

$$\text{Equation 4 : Kd = } \frac{\text{Cl}}{\text{Vd}} \quad \text{hr}^{-1}$$

$$\text{Equation 5 : T}_{1/2} = \frac{0.693}{\text{Kd}} \quad \text{hr}$$

$$\text{Equation 6 : C}_{\text{pssave}} = \frac{(\text{S})(\text{F})(\text{Dose}/\text{T})}{\text{Cl}} \quad \text{mEq/L}$$

$$\text{Equation 7 : Maintenance Dose = } \frac{(\text{Cl})(\text{C}_{\text{pssave}})(\text{T})}{(\text{S})(\text{F})} \quad \text{mEq}$$

$$\text{Equation 8 : LiCO}_3 \text{ Dose = } \frac{[\text{Lithium Dose(mEq)}](300 \text{ mg})}{(8.12 \text{ mEq})} \quad \text{mg}$$

Scr = Serum creatinine (mg/dL)

CrCl = Creatinine clearance (mL/min)

Vd = Volume of distribution (L)

Kd = Elimination Rate Constant (hr⁻¹)

$T_{1/2}$	= Half-life	(hr)
C_{pssave}	= Average Serum Concentration at steady state	(mEq/L)
S	= Salt form factor	
F	= Bioavailability	
τ	= Dosing Interval	(hr)



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

APPENDIX B

International Statistical Classification of Disease and Related Health Problem

(Tenth Revision)

ICD-10

MENTAL AND BEHAVIORAL DISORDERS

F00-F99

ORGANIC, INCLUDING SYMPTOMATIC, MENTAL DISORDERS (F00-F99)

- F00 Dementia in Alzheimer's disease**
- F01 Vascular dementia**
- F02 Dementia in other diseases classified elsewhere**
- F03 Unspecified dementia**
- F04 Organic amnesic syndrome ,not induced by alcohol and other psychoactive substances**
- F05 Delirium ,not induced by alcohol and other psychoactive substances**
- F06 Other mental disorders due to brain damage and dysfunction and to physical disease**
- F07 Personality and behavioral disorders due to brain disease,damage and dysfunction**
- F09 Unspecified organic or symptomatic mental disorder**

MENTAL AND BEHAVIORAL DISORDERS DUE TO PSYCHOACTIVE SUBSTANCE USE (F10-F19)

- F10 Mental and behavioral disorders due to use of alcohol
- F11 Mental and behavioral disorders due to use of opioids
- F12 Mental and behavioral disorders due to use of cannabinoids
- F13 Mental and behavioral disorders due to use of sedative or hypnotics
- F14 Mental and behavioral disorders due to use of cocaine
- F15 Mental and behavioral disorders due to use of other stimulants, including caffeine
- F16 Mental and behavioral disorders due to use of hallucinogens
- F17 Mental and behavioral disorders due to use of tobacco
- F18 Mental and behavioral disorders due to use of volatile solvents
- F19 Mental and behavioral disorders due to multiple drug use and use of other psychoactive substances

SCHIZOPHRENIA , SCHIZOTYPAL AND DELUSIONAL DISORDERS

(F20-F29)

- F20 Schizophrenia
- F21 Schizotypal disorder
- F22 Persistent delusional disorders
- F23 Acute and transient psychotic disorders
- F24 Induced delusional disorder
- F25 Schizoaffective disorders
- F28 Other non-organic psychotic disorders
- F29 Unspecified non-organic psychosis

MOOD (AFFECTIVE) DISORDERS (F30-F39)

- F30** Manic episode
- F31** Bipolar affective disorder
- F32** Depressive episode
- F33** Recurrent depressive disorder
- F34** Persistent mood (affective) disorders
- F38** Other mood (affective) disorders
- F39** Unspecified mood (affective) disorder

**NEUROTIC, STRESS-RELATED AND SOMATOFORM DISORDERS
(F40-F48)**

- F40** Phobic anxiety disorders
- F41** Other anxiety disorders
- F42** Obsessive-compulsive disorder
- F43** Reaction to severe stress, and adjustment disorders
- F44** Dissociative (conversion) disorders
- F45** Somatoform disorders
- F48** Other neurotic disorders

**BEHAVIORAL SYNDROMES ASSOCIATED WITH PHYSIOLOGICAL
DISTURBANCES AND PHYSICAL FACTORS (F50-F59)**

- F50** Eating disorders
- F51** Non-organic sleep disorders
- F52** Sexual dysfunction , not caused by organic disorder or disease
- F53** Mental and behavioral disorders associated with the puerperium,

not elsewhere classified

- F54 Psychological and behavioral factors associated with disorders or diseases classified elsewhere
- F55 Abuse of non-dependence-producing substances
- F59 Unspecified behavioral syndromes associated with physiological disturbances and physical factors

DISORDERS OF ADULT PERSONALITY AND BEHAVIOR (F60-F69)

- F60 Specific personality disorders
- F61 Mixed and other personality disorders
- F62 Enduring personality changes ,not attributable to brain damage and disease
- F63 Habit and impulse disorders
- F64 Gender identify disorders
- F65 Disorders of sexual preference
- F66 Psychological and behavioral disorders associated with sexual development and orientation
- F68 Other disorders of adult personality and behavior
- F69 Unspecified disorder of adult personality and behavior

MENTAL RETARDATION (F70-F79)

- F70 Mild mental retardation
- F71 Moderate mental retardation
- F72 Severe mental retardation

- F73 Profound mental retardation
- F78 Other mental retardation
- F79 Unspecified mental retardation

DISORDERS OF PSYCHOLOGICAL DEVELOPMENT (F80-F89)

- F80 Specific development disorders of speech and language
- F81 Specific development disorders of scholastic skills
- F82 Specific development disorders of motor function
- F83 Mixed specific development disorders
- F84 Pervasive development disorders
- F88 Other disorders of psychological development
- F89 Unspecified disorder of psychological development

BEHAVIORAL AND EMOTIONAL DISORDERS WITH ONSET AND ADOLESCENCE (F90-F98)

- F90 Hyperkinetic disorders
- F91 Conduct disorders
- F92 Mixed disorders of conduct and emotions
- F93 Emotional disorders with onset specific to childhood
- F94 Disorders of social functioning with onset specific to childhood and adolescence
- F95 Tic disorders
- F98 Other behavioral and emotional disorders with onset usually occurring in childhood and adolescence

UNSPECIFIED MENTAL DISORDER (F99)

F99 Mental disorder ,not otherwise specified



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
3	F 20	900	Trihexyphenidyl 2 mg tid Thioridazine 100 mg 1-2 tabs hs Vaproic acid 500 mg bid Multivitamin tid Haloperidol 10 mg tid
4	F 20	900	Chlorpromazine 100 mg hs Trihexyphenidyl 5 mg bid Haloperidol 10 mg bid Amitriptyline 25 hs
5	F 20	900	Depakine chrono 500 mg bid Fluoxetine 20 mg OD Pimozide 4 mg 2 tabs bid Thioridazine 100 4 tabs hs Haloperidol 10 mg inj. IM pm
6	F 20	600	Haloperidol 5 mg tid Carbamazepine 200 mg tid Trihexyphenidyl 5 mg tid Chlorpromazine 100 mg hs Flupenthixol decanoate 80 mg inj. IM pm agitated

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
7	F99	900	Vitamin B 1-6-12 bid Cinnarizine bid Trihexyphenidyl 2 mg bid Midodrine 2.5 mg bid Zuclophenthixol acetate 50 mg inj. IM stat Haloperidol 5 mg inj. IM pm Perphenazine 4 mg tid Cloxacillin 500 mg qid (5 days) Diclofenac 25 mg bid (3 days)
8	F 20	600	Thioridazine 100 mg hs Haloperidol 10 mg inj. IM pm Trihexyphenidyl 5 mg tid ECT pm agitated Flupenthixol decanoate 20 mg inj. IM q 1 month
9	F 20	900	Bromperidol 5 mg bid, 2 tabs hs Trihexyphenidyl 2 mg tid Diazepam 10 mg hs Flupenthixol 3 mg tid

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage regimen
10	F 20	600	Diazepam 10 mg hs Diazepam 5 mg bid Trihexyphenidyl 5 mg qid Perphenazine 8 mg hs
11	F 20	600	Diazepam 10 mg hs Chlorpromazine 100 mg hs Trihexyphenidyl 5 mg tid Haloperidol 10 mg hs Propanolol 10 mg tid Haloperidol 5 mg bid
12	F 20	900	Haloperidol 10 mg inj. IM pm Perphenazine 8 mg tid , 2 tabs hs Trihexyphenidyl 2 mg tid Chlorpromazine 100 hs
13	F 20	1200	Haloperidol 10 mg bid Trihexyphenidyl 5 mg bid Thioridazine 50 mg bid Thioridazine 100 mg hs ECT 3 times

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
14	F 20	900	ECT 6 times Haloperidol 10 mg tid Trihexyphenidyl 2 mg 1 tab prn Chlorpromazine 100 mg 2 tabs hs Chlorpromazine 50 mg tid
15	F 20	600	Carbamazepine 200 mg 1/2 tid Haloperidol 5 mg inj. IM prn Fluoxetine 20 mg OD Flunitrazepam 2 mg hs prn Hydergine FAS 1 tab hs Haloperidol 5 mg bid Chlorpromazine 50 mg inj.IMprn ECT 6 times Risperidone 2 mg 2 tabs bid
16	F 20	900	Haloperidol 10 mg tid Trihexyphenidyl 5 mg tid Chlorpromazine 200 mg hs Haloperidol decanoate 100 mg inj. IM q 1 month ECT 6 times

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
17	F 30	900	Haloperidol 5 mg inj. IM prn Trihexyphenidyl 2 mg prn EPS Flunitrazepam 2 mg hs prn insomnia Diazepam 10 mg hs Thioridazine 100 mg hs Perphenazine 8 mg bid , 2 tabs hs
18	F 39	900	Trihexyphenidyl 2 mg tid AMA 2 tabs hs Haloperidol 5 mg inj. IM prn
19	F 10	900	Haloperidol 10 mg inj. IM prn Trihexyphenidyl 2 mg prn EPS Chlorpromazine 100 mg 2 tabs hs Fluoxetine 20 mg 1 tab morning and at noon ECT 7 times Haloperidol 10 mg qid
20	F 31	900	Chlorpromazine 50 mg inj.IM prn Perphenazine 8 mg 2 tabs qid Trihexyphenidyl 5 mg prn EPS

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
21	F 39	900	Princi-B Forte bid Cavinton tid Encephabol tid Grandaxin tid Fluoxetine 20 mg OD Mianserin 30 mg hs Haloperidol 5 mg inj. IM prn
22	F 20	900	Carbamazepine 200 mg tid Haloperidol 5 mg tid Trihexyphenidyl 5 mg tid Haloperidol 10 mg inj. IM prn ECT 3 times
23	F 20	900	Haloperidol decanoate 100 mg inj. IM stat Zuclopenthixol acetate 100 mg inj. IM stat Trihexyphenidyl 2 mg bid Haloperidol 10 mg tid Haloperidol 5 mg inj. IM q 4 hrs prn

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
23 (continued)			Cavinton tid Fludilat tid Princi-B Forte bid Chlorpromazine 100 hs
24	F 20	900	ECT 6 times Chlorpromazine 200 mg tid Trihexyphenidyl 5 mg tid Haloperidol 10 mg tid Haloperidol decanoate 200 mg inj. IM q 15 days Haloperidol 5 mg inj. IM prn Veracolate bid Flunitrazepam 2 mg hs Carbamazepine 200 tid
25	F 31	900	ECT 6 times Haloperidol 10 mg tid Trihexyphenidyl 5 mg prn EPS Haloperidol 10 mg inj. IM prn Chlorpromazine 100 mg hs

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
26	F 31	1200	Haloperidol 5 mg bid Trihexyphenidyl 2 mg bid Thioridazine 100 mg hs
27	F 20	900	Pimozide 4 mg 2 tabs hs Thioridazine 50 mg hs Carbamazepine 200 mg bid
28	F 16	900	Trihexyphenidyl 2 mg bid Thioridazine 100 mg hs Haloperidol 5 mg inj. IM q 4 hrs pm Perphenazine 8 mg tid
29	F 38	900	Perphenazine 8 mg bid Trihexyphenidyl 2 mg bid Haloperidol 5 mg inj. IM pm Chlorpromazine 50 mg hs
30	F 29	900	Haloperidol 5 mg tid Trihexyphenidyl 5 mg pm EPS Haloperidol 10 mg inj. IM pm agitated Chlorpromazine 100 mg hs

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (ng/day)	Concurrent Drug Use and Dosage Regimen
34	F 20	900	Haloperidol 10 mg bid Trihexyphenidyl 2 mg bid Thioridazine 100 mg 2 tabs hs Haloperidol 5 mg inj. IM prn
35	F 20	900	Haloperidol 10 mg tid Trihexyphenidyl 5 mg tid Chlorpromazine 200 mg hs prn insomnia Haloperidol 10 mg inj. IM prn agitated
36	F 16	900	Zuclopenthixol acetate 100 mg inj. IM OD (3 days) prn agitated Chlorpromazine 100 mg tid Trihexyphenidyl 5 mg tid Thioridazine 100 tid Carbamazepine 200 tid
37	Epilepsy with psychosis	900	ECT 3 times Phenytoin 100 mg tid Phenobarbital gr. I bid Carbamazepine 200 mg tid Thioridazine 100 mg tid

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
37 (continued)			Haloperidol 10 mg inj. IM prn Vaproic acid 200 mg tid Trihexyphenidyl 5 mg tid Hyoscine 20 mg inj. IM OD (3 days)
38	F 29	900	Haloperidol 5 mg inj. IM q 4 hrs prn agitated Zuclopenthixol acetate 50 mg inj. IM stat Haloperidol 5 mg bid Trihexyphenidyl 2 mg bid Thioridazine 100 mg hs 5 % D-N/2 1000 ml IV infusion prn
39	F 38	900	Haloperidol 5 mg tid Trihexyphenidyl 2 mg bid Haloperidol 5 mg inj. IM prn Multivitamin bid ECT 3 times Carbamazepine 200 mg hs

continued..

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
39 (continued)			Zuclopenthixol 10 mg bid 5 % D-N/2 1000 ml IV infusion Haloperidol 0.5 mg bid Fero-B-Cal bid
40	F 20	900	Haloperidol 10 mg inj. IM stat Thioridazine 100 hs Haloperidol 5 mg inj. IM prn Zuclopenthixol acetate 50 mg inj. IM stat 5 % D-N/2 1000 ml IV infusion Haloperidol 5 mg qid Trihexyphenidyl 2 mg qid ECT 3 times
41	F 20	900	Zuclopenthixol decanoate 400 mg inj. IM q 1 month Carbamazepine 200 mg tid Pimozide 4 mg 2 tabs hs Thioridazine 50 mg hs Trihexyphenidyl 5 mg prn EPS Haloperidol 10 mg inj. IM prn

continued...

Patient Number	Psychiatric Diagnosis*	LiCO ₃ Dosage (mg/day)	Concurrent Drug Use and Dosage Regimen
42	F 39	900	Haloperidol 5 mg inj. IM stat Carbamazepine 200 mg tid Encephabol tid Neurobion tid Neurobion inj. IM OD *2 Haloperidol 5 mg inj. IM pm Victan 1 tab hs Chlorazepate 5 mg bid

* See in Appendix B

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

Table C 2 The Clinical Response of Patients Taking Antidepressant Drugs concomittantly with Lithium carbonate.

Patient Number	LiCO₃ Dosage (mg/day)	Antidepressant drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
4	900	amitriptyline (25 mg hs)	0.86	Good
5	900	fluoxetine (20 mg OD)	0.58	Good
15	600	fluoxetine (20 mg OD)	0.70	NO
19	900	fluoxetine (20 mg OD)	0.58	NO
21	900	fluoxetine (20 mg OD) and mianserin (30 mg hs)	0.39	Good
31	900	amineptine (100 mg morning and at noon)	1.00	Good

Table C 3 The Clinical Response of Patients Taking Anti-anxiety agents concomittantly with Lithium carbonate.

Patient Number	LiCO₃ Dosage (mg/day)	Anti-anxiety agents (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
1	600	diazepam (5 mg qid)	0.90	Good
8	600	diazepam (2 mg tid)	0.42	NO
9	900	diazepam (10 mg hs)	0.69	NO
10	600	diazepam (5 mg bid and 10 mg hs)	0.69	NO
11	600	diazepam (10 mg hs)	0.73	Good
17	900	diazepam (10 mg hs)	0.63	NO
42	900	chlorazepate (5 mg bid)	0.53	Good

Table C 4 The Clinical Response of Patients Taking Antipsychotic drugs concomittantly with Lithium carbonate.

Patient Number	LiCO₃ Dosage (mg/day)	Antipsychotic Drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
1	600	chlorpromazine (100 mg tid and 200 mg hs)	0.90	Good
2	900	pimozide (4 mg OD)	0.62	NO
3	900	thioridazine (100-200 mg hs) haloperidol (10 mg tid)	1.56	Good
4	900	chlorpromazine (100 mg hs) haloperidol (10 mg bid)	0.86	Good
5	900	pimozide (8 mg bid) thioridazine (400 mg hs)	0.58	Good

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
6	900	haloperidol (5 mg tid) chlorpromazine (100 mg hs)	0.59	Good
7	900	perphenazine (4 mg tid)	1.03	NO
8	600	thioridazine (100 mg hs)	0.42	NO
9	900	bromperidol (5 mg bid and 10 mg hs) flupenthixol (3 mg tid)	0.69	NO
10	600	perphenazine (8 mg hs)	0.69	NO
11	600	chlorpromazine (100 mg hs) haloperidol (5 mg bid and 10 mg hs)	0.73	Good

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
12	900	perphenazine (8 mg tid and 16 mg hs) chlorpromazine (100 mg hs)	0.54	Good
13	1200	haloperidol (10 mg bid) thioridazine (50 mg bid and 100 mg hs)	1.04	NO
14	900	haloperidol (10 mg tid) chlorpromazine (200 mg qid)	0.46	Good
15	600	haloperidol (5 mg bid)	0.70	Good
16	900	haloperidol (10 mg tid) chlorpromazine (200 mg hs)	0.57	Good

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
17	900	thioridazine (100 mg hs)	0.63	NO
18	900	chlorpromazine (50 mg hs)	1.07	Good
19	900	chlorpromazine (200 mg hs) haloperidol (10 mg qid)	0.58	NO
20	900	perphenazine (16 mg qid)	0.30	NO
21	900	haloperidol (5 mg inj.IM prn)	0.39	Good
22	900	haloperidol (5 mg tid)	0.94	NO
23	900	haloperidol (10 mg tid) chlorpromazine (100 mg hs)	0.53	NO
24	900	haloperidol (10 mg tid)	0.76	NO

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
25	900	haloperidol (10 mg tid) chlorpromazine (100 mg hs)	0.47	NO
26	1200	haloperidol (5 mg bid) thioridazine (100 mg hs)	1.10	Good
27	900	pimozide (8 mg hs) thioridazine (50 mg hs)	0.57	Good
28	900	thioridazine (100 mg hs) perphenazine (8 mg tid)	0.96	Good
29	900	perphenazine (8 mg bid) chlorpromazine (50 mg hs)	0.70	Good

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
30	900	haloperidol (5 mg tid) chlorpromazine (100 hs)	0.76	Good
31	900	bromperidol (5 mg hs)	1.00	Good
32	900	chlorpromazine (100 mg hs) haloperidol (5 mg tid)	0.59	Good
33	1200	haloperidol (10 mg bid) thioridazine (100 mg hs)	0.70	NO
34	900	haloperidol (10 mg bid) thioridazine (200 mg hs)	0.68	Good

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
35	900	haloperidol (10 mg tid) chlorpromazine (200 mg hs pm)	0.67	Good
36	900	chlorpromazine (100 mg tid) thioridazine (100 mg tid)	0.92	NO
37	900	thioridazine (100 mg tid)	1.75	NO
38	900	haloperidol (5 mg bid) thioridazine (50 mg bid and 100 mg hs)	1.18	Good
39	900	haloperidol (0.5 mg bid and 5 mg tid) zuclopenthixol (10 mg bid)	2.25	NO

continued..

Patient Number	LiCO ₃ Dosage (mg/day)	Antipsychotic drugs (dosage regimen)	Lithium Level (mEq/L)	Clinical Response
40	900	haloperidol (5 mg qid) thioridazine (100 mg hs)	0.70	Good
41	900	pimozide (8 mg hs) thioridazine (50 mg hs)	0.71	NO
42	900	haloperidol (5 mg inj.IM pm)	0.53	Good

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย



Vitae

Miss Panthip Promthong was born on March 6 , 1969 at Tak Hospital , Thailand. She is graduated with a Bachelor Degree in 1992 from Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok , Thailand. Her current position is a pharmacist at Srithunya Hospital.



สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย